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Introduction
!
Pancreatic cysts are being detected with increas-
ing frequency due to advances in, and rising use
of, imaging technology. A recent study suggests
that only 2% of cysts are malignant at diagnosis
[1]. The remaining patients have nonmalignant
disease, with only a 0.4% chance of malignant
transformation per year of surveillance [1]. Clini-
cians are thus faced with an epidemic of patients
with pancreatic cysts who must be triaged to sur-
veillance or surgery, the goal being to identify the
minority of cysts with high malignant potential as
early as possible while limiting unnecessary sur-
gery.
Due to the high mortality rate of pancreatic can-
cer [2], International Consensus (Sendai), Ameri-
can College of Gastroenterology, and European
Study Group on Cystic Tumours of the Pancreas
treatment guidelines take a cautious approach
and recommend resection for most cysts with
any “worrisome” feature associated with
malignancy [3–5]. However, the guideline-re-
commended criteria alone cannot accurately
stratify patients for risk of malignancy, given that
~60%−80% of surgeries reveal nonmalignant dis-
ease [1,6–10]. Such a cautious management ap-
proach results in unnecessary morbidity [8]. Con-
sequently, modalities that reduce aggressive
treatment of indolent disease while facilitating
early detection of cancer are needed to supple-
ment current guidelines [11].
Molecular profiling of pancreatic cyst fluid has
shown that high levels of high-quality DNA, loss
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Background and study aims: Current diagnostic
testing is inadequate to determine the malignant
potential of pancreatic cysts, resulting in overcau-
tious patient management. Integrated molecular
pathology (IMP) testing combines molecular a-
nalysis with first-line test results (cytology, ima-
ging, and fluid chemistry) to assess the malignant
potential of pancreatic cysts. This multicenter
study aimed to determine the diagnostic accuracy
of IMP for pancreatic adenocarcinoma, and the
utility of IMP testing under current guideline re-
commendations for managing pancreatic cysts.
Patients and methods: Patients who had under-
gone previous IMP testing as prescribed by their
physician and for whom clinical outcomes were
available from retrospective record review were
included (n=492). Performance was determined
by correlation between clinical outcome and pre-
vious IMP diagnosis (“benign”/“statistically indo-
lent” vs. “statistically higher risk [SHR]”/ “aggres-
sive”) or an International Consensus Guideline
(Sendai 2012) criteria model for “surveillance”
vs. “surgery.” The Cox proportional hazards mod-
el determined hazard ratios for malignancy.
Results: Benign and statistically indolent IMP di-
agnoses had a 97% probability of benign follow-
up for up to 7 years and 8 months from initial
IMP testing. SHR and aggressive diagnoses had re-
lative hazard ratios for malignancy of 30.8 and
76.3, respectively (both P<0.0001). Sendai sur-
veillance criteria had a 97% probability of benign
follow-up for up to 7 years and 8 months, but for
surgical criteria the hazard ratio was only 9.0
(P<0.0001). In patients who met Sendai surgical
criteria, benign and statistically indolent IMP di-
agnoses had a >93% probability of benign follow-
up, with relative hazard ratios for SHR and aggres-
sive IMP diagnoses of 16.1 and 50.2, respectively
(both P<0.0001).
Conclusion: IMP more accurately determined the
malignant potential of pancreatic cysts than a
Sendai 2012 guideline management criteria mod-
el. IMP may improve patient management by jus-
tifying more relaxed observation in patients
meeting Sendai surveillance criteria. IMP can
more accurately differentiate between the need
for surveillance or surgery in patients meeting
Sendai surgical criteria.
of heterozygosity of tumor suppressor genes, and KRAS point
mutation correlate with malignancy [12,13]. However, none of
these molecular features can individually determine malignancy
risk. Similarly, the guideline-recommended tests of imaging, cy-
tology, and fluid chemistry (amylase and/or carcinoembryonic
antigen [CEA]) may identify features that guide decisions regard-
ing surgery but cannot accurately determine the risk of malig-
nancy individually, with the exception of a definitive malignant
cytology result, which occurs in the minority of cases. In most
cases, the integration of all molecular and clinical test results is
required to provide an enhanced level of diagnostic and predic-
tive information [13,14]. Integrated molecular pathology (IMP)
testing of pancreatic cysts may be prescribed when patients lack
definitive malignant cytology results, and combines molecular a-
nalysis with clinical test results to assess malignant potential.
The aim of the current study was to establish the clinical per-
formance of IMP in diagnosing pancreatic adenocarcinoma in pa-
tients with pancreatic cysts that lack definitive malignant cytolo-
gy results, and in risk-stratifying these patients for such malig-
nancy. The clinical performance of a Sendai 2012 criteria [4]
model for surgery or surveillance decisions, and the clinical utili-
ty of using IMP under these management guidelines, was also es-
tablished in this study cohort. The ability of IMP testing to im-
prove current management strategies was then assessed.
Patients and methods
!
Design
This study was an analysis of clinical outcomes data obtained
from retrospective review of patient medical records documen-
ted in a National Pancreatic Cyst Registry, comprising 10 aca-
demic and private institutions in the United States. Approval
was obtained at each site through the site-specific institutional
review board or through Quorum IRB approval (#26022; Quor-
um Review IRB, Seattle, Washington, USA).
Patient population
All patients who had pancreatic cyst or associated duct fluid aspi-
rate tested by IMP andwere ≥18 years of age at the time of testing
were eligible for inclusion. For patients who underwent follow-
up, at least 23 months of follow-up imaging records were requir-
ed unless clear benign or malignant clinical end points occurred
within this timeframe (such patients were included). Exclusion
criteria were: i) previous pancreatic cancer, ii) any treatment for
pancreatic lesions prior to IMP testing, iii) presence of malignan-
cy known prior to or during IMP diagnosis (to ensure blinding to
actual patient outcome), iv) cases that could not be definitively
categorized as having benign or malignant outcome, v) malignant
events not related to the pancreas, and vi) diagnosis of neuroen-
docrine tumor by surgical pathology. Given that distinct areas of
disease within the same patient can differ in malignant potential
[15,16], cases in which the fine-needle aspiration (FNA) speci-
men tested was from a different area of the pancreas to where
the diagnosis of malignancy was made were also excluded (e.g.
malignant outcome diagnosed in a cystic lesion from the tail but
FNA specimen tested was from a different cystic lesion located in
the head).
IMP diagnosis
All IMP diagnoses were performed prior to the patients’ inclusion
in the study as a component of clinical testing according to the
prescribing physician’s standard of care, and were therefore all
made blinded to the eventual clinical outcome. IMP testing was
carried out by the same reference laboratory (PathFinderTG-Pan-
creas; RedPath Integrated Pathology, Inc., Pittsburgh, Pennsylva-
nia, USA), and included a pathologist’s interpretation of clinical
features (imaging characteristics, levels of atypia and cellularity,
amylase and/or CEA) integrated with results of molecular analy-
sis of pancreatic cyst fluid or associated duct fluid aspirates col-
lected by endoscopic ultrasound (EUS)-guided FNA, as per stand-
ard operating procedures (see supplementary material online).
The algorithm for determining an IMP diagnosis is summarized
in●" Table1. Each case was categorized according to the four
IMP diagnostic categories: “benign,” “statistically indolent,” “sta-
tistically higher risk (SHR),” and “aggressive.”
As the diagnostic categories have evolved over time (see supple-
mentary material online), all older cases were re-categorized ac-
cording to current criteria using all imaging, atypia and cellular-
ity, and amylase and/or CEA results available, to provide a consis-
tent set of diagnoses indicative of the current standard perform-
ance for IMP. All re-categorizations were performed blinded to
the final patient outcome.
Determination of clinical outcomes from patient records
Records from the time of initial IMP specimen collection onwards
were reviewed, including imaging, endoscopy, surgery, surgical
pathology, atypia (severe, moderate, mild, none, acellular), clini-
cal laboratory results, IMP results, and oncology records if applic-
able. De-identified patient data were compiled in a secure online
database (OpenClinica version 3.1.3; OpenClinica LLC, Waltham,
Massachusetts, USA).
Clinical outcomes were categorized as “benign” or “malignant”
(pancreatic adenocarcinoma). Benign outcomes included benign
surgical pathology results, low-grade or intermediate-grade (in-
cluding moderate) dysplasia, resolution of cyst (i. e. cyst not visi-
ble via imaging upon follow-up visit), or clinical follow-up by
imaging (EUS, magnetic resonance imaging, computed tomog-
raphy, endoscopic retrograde cholangiopancreatography) for
≥23 months without evidence of malignant outcome. This fol-
Table 1 Criteria for integrated molecular pathology diagnostic categories.
Diagnostic category Molecular criteria1 Co-existing concerning clinical features2
Benign DNA lacks molecular criteria Not considered for this diagnosis
Statistically indolent DNA meets 1 molecular criterion None
SHR DNA meets 1 molecular criterion 1 or more
Aggressive DNA meets at least 2 molecular criteria Not considered for this diagnosis
SHR, statistically higher risk.
1 Four molecular criteria that have been independently correlated with pancreatic malignancy or high-grade dysplasia are used to make an integrated molecular pathology diag-
nosis: i) a single high-clonality mutation, ii) elevated level of high-quality DNA, iii) multiple low-clonality mutations; iv) a single low-clonality oncogene mutation [13].
2 Include any of the following: cyst size>3cm, growth rate>3mm/year, duct dilation>1cm, carcinoembryonic antigen level>1000ng/mL, cytologic evidence of high-grade dys-
plasia.
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low-up period was selected as a reasonable time for latent pan-
creatic adenocarcinoma to become evident. Malignant outcomes
were determined by conclusive indications of malignancy, such
as surgical pathology diagnosis of high-grade dysplasia, carcino-
ma in situ, or adenocarcinoma, malignant cytology results (un-
known during IMP diagnosis; patients were excluded if known),
clinically confirmed pancreatic cancer in patient records, and
death attributed to pancreatic cancer. The date of malignant out-
come was defined as the earliest date at which a definitive diag-
nosis of malignancy could be made.
Performance characteristics
The performance characteristics of IMP were evaluated by deter-
mining the correlation between blinded IMP diagnoses and ac-
tual clinical outcomes frommedical record review. Accuracy, sen-
sitivity, specificity, negative predictive value (NPV), and positive
predictive value (PPV) for malignant outcome were calculated
using 2×2 tables. The benign and statistically indolent categories
were considered to be low malignant potential categories, and
the SHR and aggressive categories were considered to be high
malignant potential categories.
The performance of a model of the Sendai 2012 criteria for mana-
ging this same cohort of patients according to imaging, cytologic,
and amylase and/or CEA results was determined in the sameway.
In the model, patients were categorized as having met Sendai
2012 “surveillance” criteria (low malignant potential) or Sendai
2012 “surgery” criteria (high malignant potential). The surgery
category required at least one of the following features: presence
of obstructive jaundice in a patient with a cystic lesion of the
head, cyst size >3cm, enhancing solid component or definite
mural nodule confirmed by EUS, severe (i. e. suspicious) cytology,
main duct involvement, main duct dilation of ≥1cm, abrupt
changes in duct caliber, or a presumptive diagnosis of mucinous
cystic neoplasm based on cytology report indications of mucin.
The surveillance category lacked all such features. This model
does not match the published Sendai 2012 guidance exactly, as
the patient cohort included in the study comprised only patients
for whom IMP was ordered as part of standard clinical care (i. e.
those with negative, nondiagnostic, indeterminate or acellular
cytology results) and not all possible pancreatic cyst patients.
Statistical analysis
Statistical analysis was performed using R statistical software (r-
project.org). Exact binomial tests were used to determine statis-
tical significance and 95% confidence intervals (CI) for accuracy,
sensitivity, specificity, NPV, and PPV. Comparisons between sur-
gical outcome and all clinical outcome populations were per-
formed using Fisher’s exact test. Comparisons of sensitivity and
specificity between IMP and the Sendai 2012 model were per-
formed using McNemar’s test, and comparisons of NPV and PPV
between IMP and the Sendai model were made using a weighted
generalized scoring statistic [17].
Malignancy-free outcome from the date of initial IMP diagnosis
was estimated using Kaplan–Meier curves. The hazard ratio for
risk of malignant outcome was calculated using the univariate
Cox proportional hazards model for the SHR and aggressive IMP
categories vs. the benign and statistically indolent categories
combined. The same univariate Cox proportional hazards model
was used to determine the hazard ratio between the surgery and
surveillance categories of the Sendai model. For subcategory
comparisons, such as aggressive vs. SHR, multiple comparison
adjustment with Tukey’s test was used to determine the hazard
ratio. A post hoc, multivariate Cox proportional hazards analysis
was also performed, adjusting for age, sex, symptoms related to
pancreatic disease, patient history of cancer (nonpancreatic),
and patient family history of anymalignancy, to confirm the find-
ings of the univariate analysis.
Results
!
Patients
The study was carried out between April 2011 and August 2013.
Records for 1864 patients were reviewed (patients undergoing
EUS-FNA and IMP testing between January 2005 and April
2013). Of these, 1372/1864 cases did not meet study inclusion
criteria: 1280 had insufficient follow-up to confirm benign out-
come (<23 months) and 92 met exclusion criteria. Overall, 492/
1864 patients were included (338 women and 154 men; mean
age at IMP testing 64.9 years). Of these, 468/492 IMP diagnoses
were re-categorized prior to analysis, and 24/492 were already
classified according to the current four IMP diagnostic categories.
The sources of clinical outcomes with follow-up time are shown
in Supplementary●" Table e2 (available online). For outcomes
based on imaging surveillance, follow-up of ≥3 years was avail-
able for 46% of patients. Pancreatic cyst clinical characteristics
and surgical pathology classifications are shown in Supplemen-
tary●" Table e3 and●" Table e4 (available online).
Clinical performance characteristics of IMP
The overall accuracy, NPV, and specificity of IMP for malignant
outcome were high (90%, 97%, and 91%, respectively) (●" Table
5). The sensitivity of IMP for malignant outcome was 83% and
the PPV was 58% (●" Table5). Overall accuracy of IMP in the sub-
set of surgical outcomes was 10% lower than that in the all-out-
comes population (Supplementary●" Table e6, available online).
For Kaplan–Meier analysis, the median follow-up time for pa-
tients with benign and statistically indolent diagnoses was 35
Table 5 Performance characteristics of integrated molecular pathology di-
agnosis and themodel of the international consensus guideline (Sendai 2012)
criteria regarding ability to differentiate between cysts with and without ma-
lignant potential (n = 492).
IMP
% [95%CI]
Sendai 2012 model
% [95%CI]
P for IMP vs.
Sendai 2012
model
Accuracy 89.6
[86.6–92.2]
52.2
[47.7–56.7]
N/A
Sensitivity 83.3
[72.1–91.4]
90.9
[81.2–96.6]
0.17
Specificity 90.6
[87.4–93.2]
46.2
[41.4–51.1]
< 0.0001
NPV 97.2
[95.1–98.6]
97.0
[93.7–98.9]
0.88
PPV 57.9
[47.3–68.0]
20.8
[16.2–25.9]
< 0.0001
Positive
likelihood
ratio
8.9
[6.5–12.2]
1.7
[1.5–1.9]
< 0.0001
Negative
likelihood
ratio
0.2
[0.1–0.3]
0.2
[0.1–0.4]
0.88
IMP, integrated molecular pathology; CI, confidence interval; NPV, negative predictive
value; PPV, positive predictive value; N/A, not applicable.
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months (range 23 months – 7 years 8 months). Patients with
these diagnoses had a 97% probability of a benign outcome for
up to 7 years and 8 months from initial IMP testing (●" Fig.1).
There were only a few instances of malignant outcome (11/397)
in the benign and statistically indolent categories, and all of these
malignancies occurred within 23 months of initial IMP diagnosis
(●" Fig.1).
Malignant outcome was confirmed in most patients with aggres-
sive IMP diagnoses (88%) and in 47% with SHR diagnoses (Sup-
plementary●" Table e6, available online). Of the SHR and aggres-
sive cases with malignant outcome, most were confirmed within
3 months of IMP testing (●" Fig.1). The probability of a benign
outcome <1 year after initial IMP testing was 35% in patients
with SHR diagnoses and 9% in those with aggressive diagnoses,
with univariate hazard ratios for malignant outcome of 30.8 and
76.3, respectively, relative to those with benign and statistically
indolent diagnoses (both P<0.0001) (Supplementary ●" Table
e7, available online). The hazard ratio for aggressive diagnosis re-
lative to SHR diagnosis was 2.4 (P<0.01, confirmed by Tukey’s
multiple comparison test). After adjusting for covariates, hazard
ratios for the SHR (27.8) and aggressive (79.2) categories were
also statistically significant (both P<0.0001) (Supplementary
●" Table e7, available online).
Clinical performance characteristics of Sendai 2012
model
The performance characteristics of the Sendai 2012 model in this
patient cohort are shown in●" Table5. Overall accuracy of the
Sendai model was 13% lower for the subset of surgical pathology
outcomes only compared with all outcomes (Supplementary
●" Table e8, available online). In Kaplan–Meier analysis, patients
who met Sendai surveillance criteria had a 97% chance of having
a benign outcome for up to 7 years and 8 months from initial IMP
testing (●" Fig.2). However, patients who met Sendai criteria for
surgery also had a high probability (75%) of having a benign out-
come at this time (●" Fig.2). The univariate hazard ratio for malig-
nant outcome was 9.0 for those who met Sendai surgical criteria
relative to those who met surveillance criteria (P<0.0001) (Sup-
plementary●" Table e7, available online). After adjusting for cov-
ariates, the hazard ratio for those who met surgical criteria re-
mained statistically significant (8.1, P<0.0001) (Supplementary
●" Table e7, available online).
Clinical utility of IMP testing in patients who met Sendai
2012 model criteria for surgery or surveillance
Comparison of IMP with the Sendai 2012 model showed similar
sensitivity, NPV, and negative likelihood ratio (P>0.17) but statis-
tically better specificity, PPV, and positive likelihood ratio for IMP
(all P<0.0001). The majority of patients who met Sendai criteria
for surgery actually had benign outcomes (79% [229/289]; Sup-
plementary●" Table e8, available online). Of these patients meet-
ing Sendai surgical criteria but having benign clinical outcomes,
84% (193/229) had an IMP diagnosis of benign or statistically in-
dolent (Supplementary●" Table e9, available online).
Kaplan–Meier curves for the ability of IMP to further improve
risk stratification of patients who met Sendai criteria for surgery
are shown in●" Fig.3. The probability of benign outcome at fol-
low-up for benign and statistically indolent IMP diagnoses in pa-
tients who met Sendai criteria for surgery was 93% and 97%,
respectively, even up to ~5 years after initial IMP testing. There
was no statistical difference in the univariate hazard ratios be-
tween benign and statistically indolent diagnoses (P>0.46, con-
firmed by Tukey’s multiple comparison test). By contrast, the
probability of benign outcome at follow-up in SHR and aggressive
IMP diagnoses wasmuch lower (36% and 5%, respectively). In pa-
tients who met Sendai surgical criteria, the univariate hazard ra-
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Fig.1 Integrated molecular pathology (IMP) risk stratification for malig-
nant potential in all patients (n=492). Kaplan–Meier analysis for probability
of a benign outcome at follow-up for each IMP diagnostic category.
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Fig.2 Sendai 2012 risk stratification for malignant potential in all patients
(n=492). Kaplan–Meier analysis for probability of a benign outcome at fol-
low-up in patients who met Sendai 2012 model criteria categories for sur-
veillance or surgery.
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Fig.3 Integrated molecular pathology (IMP) risk stratification for malig-
nant potential in patients who met Sendai 2012 model criteria for surgery.
Kaplan–Meier analysis for probability of benign outcome at follow-up for
each IMP diagnostic category.
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tios for malignant outcome were 16.1 (95%CI 7.6–34.3) for SHR
and 50.2 (95%CI 22.6–111.5) for aggressive IMP diagnoses rela-
tive to benign and statistically indolent combined (both P<
0.0001).
Of the patients who met Sendai surveillance criteria, 197/203
had benign outcomes and 6/203 had malignant outcomes (Sup-
plementary●" Table e9, available online). Surveillance criteria
were confirmed by benign or statistically indolent IMP diagnoses
in 98% (193/197) of these patients. Of the six false-negative cases
identified by Sendai criteria for surveillance, four were correctly
diagnosed as SHR or aggressive disease by IMP.
Discussion
!
The greatest challenge in managing pancreatic cysts is the accu-
rate stratification of patients at risk of malignancy so that unne-
cessary surgery is minimized. As none of the currently available
guideline-recommended tests can accurately determine malig-
nant potential in pancreatic cysts, additional strategies that pro-
vide reliable information regarding the presence, absence, or in-
creased risk of malignancy are needed to help guide patient man-
agement.
This study showed that IMP provides clinically valid and useful
diagnostic information that can improvemanagement of patients
with pancreatic cysts. The high NPV, specificity, and probability
of follow-up with benign outcome indicate that benign and sta-
tistically indolent IMP diagnoses reliably predict benign disease.
IMP therefore identifies patients in whom surgery is avoidable
and surveillance is justified. Furthermore, in patients with be-
nign or statistically indolent diagnoses, no cases of malignant
outcome occurred beyond 2 years of follow-up from initial IMP
diagnosis, which should help guide surveillance intervals. The
sensitivity and PPV of IMP for malignant outcome indicates that
aggressive and SHR IMP diagnoses are reliable predictors of ma-
lignancy. Moreover, the hazard ratios for risk of malignant out-
come were significantly higher for the SHR and aggressive IMP
categories relative to benign/statistically indolent, and for the ag-
gressive category relative to SHR. IMP therefore presents a useful
risk stratification tool for clinicians to differentiate benign and in-
dolent cysts from those at higher risk of malignancy that require
close surveillance or immediate surgery.
The application of the Sendai 2012 model to this patient cohort
emphasizes a well-documented problem: too many patients un-
dergo surgery for benign pancreatic cysts [1,6–10]. The NPV,
negative likelihood ratio, and sensitivity of the Sendai criteria
were high, as was the probability of benign outcome at follow-
up.However, the accuracy, specificity, positive likelihood ratio,
and PPV were low due to the high number of false-positive re-
sults for malignant outcomewhen applying surgical criteria. Con-
sequently, patients meeting Sendai criteria for surgery had only a
9.0-times higher risk of malignant outcome, which would result
in many surgeries on benign or indolent cysts. Nearly identical
results were observed when European treatment guideline crite-
ria for surgery and surveillance [5] were evaluated (data not
shown). Of note, performance of the Sendai 2012 criteria was ex-
amined only in patients for whom IMP testing had been pre-
scribed (those with negative, nondiagnostic, indeterminate or
acellular cytology results), rather than in all possible pancreatic
cyst patients. Thus, the study cohort did not include those with
the “high-risk stigmata” of malignant cytology prior to IMP test-
ing, which is an absolute indication for surgery according to cur-
rent guidance, because additional information is not needed in
these patients to determine whether surgery is required.
Although the Sendai 2012 guidance refers specifically to the
management of intraductal papillary mucinous neoplasm and
mucinous cystic neoplasm, we believe that from the perspective
of a practicing physician operating in the clinic, all cysts are con-
sidered mucinous until proven otherwise. Given that the Sendai
2012 guidance is intended to manage surveillance or surgery de-
cisions, we think it is reasonable to assume that patients who do
not havemucinous cystic neoplasm or other intraductal papillary
mucinous neoplasm criteria for surgery would undergo surveil-
lance, which is how the Sendai 2012 criteria were modeled in
the current analysis, and this is reflected in the European guide-
lines. Also, we considered a cyst size of >3cm to be an indication
for surgery, but recognize that the Sendai 2012 guidance is slight-
ly more complex with respect to cyst size. To address this differ-
ence, the analysis was repeated with complete exclusion of cyst
size from the surveillance and surgery categories; this had mini-
mal impact on the performance of the Sendai 2012 model in this
cohort (only 8.0-times higher risk of malignant outcome for pa-
tients meeting surgical criteria; data not shown). Furthermore,
in this cohort, the addition of CEA ≥192ng/mL as a criterion for
mucin, and thus surgery, decreased the accuracy of the Sendai
model due to an increase in false-positive cases without any re-
duction in false-negative cases (only 5.9-times higher risk of ma-
lignant outcome for patients meeting surgical criteria; data not
shown). Omitting all presumptive cytologic and CEA criteria for
mucinous cysts from the Sendai model only slightly improved
risk stratification due to a modest reduction in false-positive
cases (11.6-times higher risk of malignant outcome for patients
meeting surgical criteria; data not shown). Regardless of these
modeling limitations, the performance of the Sendai criteria in
our model paralleled that of another study with a larger cohort
(n=767) and similar follow-up time (PPV 23% and NPV 99.5%)
[18].
Comparison of the performance characteristics of IMP with those
of the Sendai 2012 model indicated similar sensitivity, negative
likelihood ratio, and NPV for malignancy and similar probability
of benign outcome at follow-up.By contrast, there were statisti-
cally significant differences in specificity, positive likelihood ra-
tio, and PPV favoring IMP due to a reduction in false-positive
cases. Such differences were further emphasized when Sendai
criteria and IMP risk stratification capabilities were compared.
Patients who had high malignant potential per IMP diagnoses
had a much higher risk of malignant outcome than those who
met Sendai criteria for high malignant potential.
To examine the clinical utility of using IMP under current guide-
line-recommended management strategies, IMP performance
was evaluated in patients meeting Sendai 2012 criteria for sur-
gery and for surveillance. In patients meeting Sendai surgical
criteria, benign and statistically indolent IMP diagnoses correctly
predicted benign outcomes in the majority, with a >93% prob-
ability of benign outcome at follow-up.Comparatively, patients
with SHR and aggressive diagnoses were at higher risk of malig-
nant outcome. Thus, IMP can more accurately stratify the malig-
nant potential than guideline criteria for surgery. Although the
majority of patients meeting Sendai 2012 criteria for surveillance
had benign outcomes, some false-negatives were present. IMP
was not only able to confirm surveillance in nearly all of these pa-
tients but was also able to correctly identify most false-negative
cases. IMP therefore improves guideline-recommended manage-
ment strategies by justifying more relaxed observation in pa-
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tients likely to have benign disease course, and closer surveil-
lance or surgery in patients at higher risk of pancreatic adenocar-
cinoma.
The primary limitation of this study is the retrospective nature of
the outcomes data, which are subject to the drawbacks inherent
to this type of study, including insufficient or inaccessible docu-
mentation, which resulted in many cases not meeting the pre-
specified inclusion criterion of follow-up ≥23 months. Data that
would be used for the categorization of patients according to
Sendai 2012 criteria were also not specified in a significant pro-
portion of patients, as the collection of information was started
prior to publication of the 2012 guidelines. The cohort examined
also precluded assessment of the Sendai surgical criterion of ma-
lignant cytology, because patients with initial malignant cytology
results do not require IMP testing. However, as noted above, an
independent study showed very similar results to those reported
here whenmalignant cytology was included [18]. Finally, consid-
ering the nature of these lesions, the mean follow-up period for
benign disease in this study is too short for firm conclusions to
be made beyond 3 years; similar analyses with longer follow-up
are desirable.
Retrospective record review is currently the only feasible method
for assessing more recent diagnostic criteria or tests due to the
benign nature of most pancreatic cysts. The reference standard
in such a study is surgical pathology. However, surgery-only po-
pulations do not reflect the total patient population for which di-
agnostic criteria are intended, which includes patients who will
have a benign disease course and thus, in reality, undergo sur-
veillance. An advantage of the current study is that it examined
performance of diagnostic criteria in a population comprising
both surgery and surveillance subpopulations, thus providing a
more real-life evaluation for the performance of both guideline
criteria and IMP testing. The overall accuracy of both IMP and
the Sendai 2012 model was statistically lower for the analysis of
surgical outcomes only compared with the analysis of all types of
outcome.
In conclusion, an IMP diagnosis of benign or statistically indolent
is a highly reliable predictor that a pancreatic cyst is benign and
has low potential for malignant transformation over a median
follow-up of ~3 years in patients who lack definitive malignant
cytology results. Furthermore, SHR and aggressive IMP diagnoses
identify patients who are at significantly higher risk of pancreatic
adenocarcinoma. IMP is more accurate than Sendai 2012 criteria
in risk stratifying patients according to their potential for pancre-
atic adenocarcinoma. IMP may therefore improve guideline-re-
commended patient management strategies by increasing confi-
dence that observation is more appropriate in the majority of pa-
tients, who are likely to have a benign disease course. In a minor-
ity of patients, closer surveillance or surgical consultationmay be
necessary due to significantly higher risk of pancreatic adenocar-
cinoma. IMP is therefore able to limit the overtreatment of incon-
sequential disease while accurately detecting cancer, which is an
essential characteristic of a clinically useful diagnostic test [11].
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